News & Updates

Individuals with acute COVID-19 who receive prompt antiviral treatment, such as ensitrelvir, nirmatrelvir, or molnupiravir, in the outpatient setting may be less likely to experience post–COVID-19 condition (PCC) compared with those who receive no treatment.

Treatment with gedatolisib plus fulvestrant, with or without palbociclib, significantly improves progression-free survival (PFS) in patients with HR+/HER2– PIK3CA wild-type (WT) advanced breast cancer (ABC) compared with fulvestrant alone, according to the VIKTORIA-1 trial presented at ESMO Breast Cancer 2026.